Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2236 to 2250 of 7710 results

  1. Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376

    Awaiting development [GID-TA11608] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development [GID-TA11360] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    Awaiting development [GID-TA11021] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development [GID-TA11438] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development [GID-TA11402] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development [GID-TA11428] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284

    In development [GID-TA11334] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Osteoporosis

    Awaiting development [GID-QS10188] Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development [GID-TA11058] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  14. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  15. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    Awaiting development [GID-TA11416] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development